Dividend-News
Daily dividend news for investors in dividend stocks
Dividends On Sale: The Big Drop In Bristol-Myers Is Worth Buying
-
Published Fri, 03 Aug 2012 16:49:06 -0400 on Seeking Alpha
Bristol-Myers Squibb (BMY) shares were recently making new 52-week highs at just over $36 per share, but that all changed after the company announced disappointing news on a hepatitis drug candidate called INX-189, that it acquired when it bought Inhibitex for about $2.5 billion. This candidate was in phase 2 clinical trials when safety issues developed and caused the drug maker to suspend the study. Investors saw this as good news for Gilead Sciences (GILD) which shot up about 7%, since it has a potential hepatitis treatment that is further along in development, (now in phase 3 trials). If that was not enough bad news for Bristol-Myers shareholders in one day, it was also reported that a Bristol-Myers executive was charged with insider trading. While this only appears to have an impact on the executive, it was not great news for investors and it probably had little to no impact... Read more
Stock name ISIN Last trade P/E Earnings/Share Dividend/Share Dividend yield BRISTOL-MYERS SQUIBB 
US1101221083 43.30 48.8 0.88 1.40 3.23 GILEAD SCIENCES
US3755581036 56.30 36.5 0.00 0.00 0.00